Present address: Novartis SA, CH-1260 Nyon.
Screening of Non-Alkaloidal Natural Compounds as Acetylcholinesterase Inhibitors
Version of Record online: 24 JUN 2004
Copyright © 2004 Verlag Helvetica Chimica Acta AG, Zürich
Chemistry & Biodiversity
Volume 1, Issue 6, pages 819–829, June 2004
How to Cite
Brühlmann, C., Marston, A., Hostettmann, K., Carrupt, P.-A. and Testa, B. (2004), Screening of Non-Alkaloidal Natural Compounds as Acetylcholinesterase Inhibitors. Chemistry & Biodiversity, 1: 819–829. doi: 10.1002/cbdv.200490064
- Issue online: 24 JUN 2004
- Version of Record online: 24 JUN 2004
- Manuscript Received: 19 FEB 2004
Acetylcholinesterase (AChE) inhibitors are currently the only approved therapy for the treatment of Alzheimer's disease, only a limited number of drugs are commercially available. A library of non-alkaloidal natural compounds was investigated. To this end, a convenient microtitre plate method for assaying AChE inhibition, which allows a complete kinetic analysis of AChE inhibitors, was developed. Seven active compounds with Ki values in the micromolar range were identified, six of which were xanthones. This is the first report that a promising potential for AChE inhibition exists in such non-nitrogenous natural compounds. Furthermore, four xanthones among these xanthones had already been described as monoamine oxidase (MAO) inhibitors, making then dual AChE/MAO inhibitors of great interest.